The Motley Fool
22 Jun 2026, 21:54 UTC · 15w ago
Impact · against what's priced in
AbbVie's $10.9 billion offer for Apogee Therapeutics provides a concrete path to replenish its immunology pipeline ahead of future patent cliffs. For Apogee, the all-cash buyout at $135.11 per share represents an immediate and significant valuation reset.
No priced-in read yet
What the story claims
3 claims · scored −1 bearish … +1 bullish
AbbVie has proposed an all-cash acquisition of Apogee Therapeutics at $135.11 per share, valuing the company at approximately $10.9 billion.
So whatA multi-billion dollar acquisition creates immediate, significant value for the target company's shareholders and resets its valuation.
More positive than 99% of claims this week
The acquisition is intended to reload AbbVie's immunology pipeline with Apogee's clinical-stage treatments for asthma, atopic dermatitis, and eosinophilic esophagitis.
Continue reading
5 related stories
The proposal of an all-cash acquisition at $135.11 per share creates immediate value, driving a nearly 50% surge in the share price.
Read from the article alone
No priced-in read yet
Acquiring Apogee allows AbbVie to reload its immunology pipeline with clinical-stage treatments for asthma and atopic dermatitis to replace future revenue loss from Rinvoq and Skyrizi.
Read from the article alone
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 79% of claims this week
Market expectations suggest the deal is likely to close in Q3, as Apogee shares are trading only 2% below the offer price.
More positive than 66% of claims this week
Which stocks this story touches
More positive than 99% of ticker scores this week
The company is being acquired by AbbVie for $10.9 billion, causing a nearly 50% surge in share price.
More positive than 76% of ticker scores this week
The acquisition of Apogee is viewed positively as it reloads AbbVie's immunology pipeline with blockbuster potential.
Near neutral — 91% of ticker scores this week are stronger
Mentioned as a peer in the sector with a negligible price change.
Near neutral — 91% of ticker scores this week are stronger
Mentioned as a peer in the sector with a negligible price change.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
1h ago
More positive than 34% of relationship scores this week
[mutual] Both companies are focused on biologic immunology and inflammatory disease therapies.
More positive than 34% of relationship scores this week
[mutual] Both companies are focused on biologic immunology and inflammatory disease therapies.
+1.9%
Price agrees with the score
$135.07 vs $132.55 close before publication (Jun 22) · not market-adjusted
APGE chart →+14.2%
Price agrees with the score
$262.67 vs $230.01 close before publication (Jun 22) · not market-adjusted
ABBV chart →
